Gilad Yahalom

Dr. Gilad Yahalom

Department of Neurology and the Movement Disorders Unit, Shaare Zedek Medical Center, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
GYGilad Yahalom
Gilad Yahalom
LGLior Greenbaum
Lior Greenbaum
Simon Israeli-KornSimon Israeli-Korn
Simon Israeli-Korn
TFTsvia Fay-Karmon
Tsvia Fay-Karmon
VLVered Livneh
Vered Livneh
SHSharon Hassin-Baer
Sharon Hassin-Baer

Verified
Journal Article
Open access
PDF file
Aliaksandr SkrahinAliaksandr Skrahin
Aliaksandr Skrahin
MHMia Horowitz
Mia Horowitz
MIMajdolen Istaiti
Majdolen Istaiti
VSVolha Skrahina
Volha Skrahina
JLJan Lukas
Jan Lukas
Ari ZimranAri Zimran
Ari Zimran
GBA1-associated Parkinson’s disease (GBA1-PD) is increasingly recognized as a distinct entity within the spectrum of parkinsonian disorders. This review explores the unique pathophysiological features, clinical progression, and genetic underpinnings that differentiate GBA1-PD from idiopathic Parkinson’s disease (iPD). GBA1-PD typically presents with earlier onset and more rapid progression, with a poor response to standard PD medications. It is marked by pronounced cognitive impairment and a higher burden of non-motor symptoms compared to iPD. Additionally, patients with GBA1-PD often exhibit a broader distribution of Lewy bodies within the brain, accentuating neurodegenerative processes. The pathogenesis of GBA1-PD is closely associated with mutations in the GBA1 gene, which encodes the lysosomal enzyme beta-glucocerebrosidase (GCase). In this review, we discuss two mechanisms by which GBA1 mutations contribute to disease development: ‘haploinsufficiency,’ where a single functional gene copy fails to produce a sufficient amount of GCase, and ‘gain of function,’ where the mutated GCase acquires harmful properties that directly impact cellular mechanisms for alpha-synuclein degradation, leading to alpha-synuclein aggregation and neuronal cell damage. Continued research is advancing our understanding of how these mechanisms contribute to the development and progression of GBA1-PD, with the ‘gain of function’ mechanism appearing to be the most plausible. This review also explores the implications of GBA1 mutations for therapeutic strategies, highlighting the need for early diagnosis and targeted interventions. Currently, small molecular chaperones have shown the most promising clinical results compared to other agents. This synthesis of clinical, pathological, and molecular aspects underscores the assertion that GBA1-PD is a distinct clinical and pathobiological PD phenotype, necessitating specific management and research approaches to better understand and treat this debilitating condition.

8 February 2011 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GYGilad Yahalom
Gilad Yahalom
SKS. Kivity
S. Kivity
MLM. Lidar
M. Lidar
AVA. Vaknin-Dembinsky
A. Vaknin-Dembinsky
DKD. Karussis
D. Karussis
ALA. Livneh
A. Livneh

9 September 2014 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GYGilad Yahalom
Gilad Yahalom
YAYair Anikster
Yair Anikster
RHRuth Huna-Baron
Ruth Huna-Baron
CHChen Hoffmann
Chen Hoffmann
LBLubov Blumkin
Lubov Blumkin
SHSharon Hassin-Baer
Sharon Hassin-Baer

29 May 2021 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
GYGilad Yahalom
Gilad Yahalom
TFTsvia Fay-Karmon
Tsvia Fay-Karmon
VLVered Livneh
Vered Livneh
SISimon Israeli-Korn
Simon Israeli-Korn
LELilach Ephraty
Lilach Ephraty
SHSharon Hassin-Baer
Sharon Hassin-Baer

1 June 2018 in International Journal Of Impotence Research
Verified
Journal Article
Closed access
PDF file
GBGila Bronner
Gila Bronner
Simon Israeli-KornSimon Israeli-Korn
Simon Israeli-Korn
SHSharon Hassin-Baer
Sharon Hassin-Baer
GYGilad Yahalom
Gilad Yahalom